BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 22080849)

  • 1. Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study.
    Faggiano A; Ferolla P; Grimaldi F; Campana D; Manzoni M; Davì MV; Bianchi A; Valcavi R; Papini E; Giuffrida D; Ferone D; Fanciulli G; Arnaldi G; Franchi GM; Francia G; Fasola G; Crinò L; Pontecorvi A; Tomassetti P; Colao A
    J Endocrinol Invest; 2012 Oct; 35(9):817-23. PubMed ID: 22080849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiological Data and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: Insights From Tertiary Referral Hospitals in Latvia.
    Ptasnuka M; Ozolins A; Narbuts Z; Truskovs A; Sperga M; Plaudis H
    World J Surg; 2020 Feb; 44(2):585-593. PubMed ID: 31605174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
    Mosquera C; Koutlas NJ; Fitzgerald TL
    Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.
    Masui T; Ito T; Komoto I; Uemoto S;
    BMC Cancer; 2020 Nov; 20(1):1104. PubMed ID: 33189127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural History of MEN1 GEP-NET: Single-Center Experience After a Long Follow-Up.
    Giudici F; Cavalli T; Giusti F; Gronchi G; Batignani G; Tonelli F; Brandi ML
    World J Surg; 2017 Sep; 41(9):2312-2323. PubMed ID: 28429092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres.
    Frizziero M; Wang X; Chakrabarty B; Childs A; Luong TV; Walter T; Khan MS; Morgan M; Christian A; Elshafie M; Shah T; Minicozzi A; Mansoor W; Meyer T; Lamarca A; Hubner RA; Valle JW; McNamara MG
    World J Gastroenterol; 2019 Oct; 25(39):5991-6005. PubMed ID: 31660035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database.
    Panzuto F; Partelli S; Campana D; de Braud F; Spada F; Cives M; Tafuto S; Bertuzzi A; Gelsomino F; Bergamo F; Marcucci S; Mastrangelo L; Massironi S; Appetecchia M; Filice A; Badalamenti G; Bartolomei M; Amoroso V; Landoni L; Rodriquenz MG; Valente M; Colao A; Isidori A; Fanciulli G; Bollina R; Ciola M; Butturini G; Marconcini R; Arvat E; Cinieri S; Berardi R; Baldari S; Riccardi F; Spoto C; Giuffrida D; Gattuso D; Ferone D; Rinzivillo M; Bertani E; Versari A; Zerbi A; Lamberti G; Lauricella E; Pusceddu S; Fazio N; Dell'Unto E; Marini M; Falconi M
    Endocrine; 2024 Apr; 84(1):42-47. PubMed ID: 38175391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study.
    Zhang X; Ma L; Bao H; Zhang J; Wang Z; Gong P
    BMC Endocr Disord; 2014 Jul; 14():54. PubMed ID: 25001493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis.
    Laffi A; Spada F; Bagnardi V; Frassoni S; Pisa E; Rubino M; Barberis M; Fazio N
    J Endocrinol Invest; 2022 Feb; 45(2):317-325. PubMed ID: 34282554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients.
    Baeg K; Harris C; Naparst MS; Ahn E; Thapi S; Martin J; Rustgi S; Mhango G; Wisnivesky J; Kim MK
    BMC Cancer; 2021 Feb; 21(1):146. PubMed ID: 33563241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
    ; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
    Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological features and prognostic factors associated with gastroenteropancreatic mixed neuroendocrine non-neuroendocrine neoplasms in Chinese patients.
    Huang YC; Yang NN; Chen HC; Huang YL; Yan WT; Yang RX; Li N; Zhang S; Yang PP; Feng ZZ
    World J Gastroenterol; 2021 Feb; 27(7):624-640. PubMed ID: 33642833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study.
    Feola T; Puliani G; Sesti F; Modica R; Centello R; Minotta R; Cannavale G; Di Meglio S; Di Vito V; Lauretta R; Appetecchia M; Colao A; Lenzi A; Isidori AM; Faggiano A; Giannetta E
    J Endocrinol Invest; 2022 Apr; 45(4):849-857. PubMed ID: 35040099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial impact of a systematic multidisciplinary approach on the management of patients with gastroenteropancreatic neuroendocrine tumor.
    Tamagno G; Sheahan K; Skehan SJ; Geoghegan JG; Fennelly D; Collins CD; Maguire D; Traynor O; Brophy DP; Cantwell C; Swan N; McGowan L; O'Toole D; O'Shea D
    Endocrine; 2013 Oct; 44(2):504-9. PubMed ID: 23471696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intervention in gastro-enteropancreatic neuroendocrine tumours.
    Baudin E; Planchard D; Scoazec JY; Guigay J; Dromain C; Hadoux J; Debaere T; Elias D; Ducreux M
    Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):855-65. PubMed ID: 23582924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany.
    Scherübl H; Streller B; Stabenow R; Herbst H; Höpfner M; Schwertner C; Steinberg J; Eick J; Ring W; Tiwari K; Zappe SM
    World J Gastroenterol; 2013 Dec; 19(47):9012-9. PubMed ID: 24379626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An 11-year retrospective study: clinicopathological and survival analysis of gastro-entero-pancreatic neuroendocrine neoplasm.
    Liu H; Xie R; Zhao Z; Xu D; Yang K; Ding M; Tan D; Liao W; Han X; Zhang J; Shen D; Yuan J; Xu Z; Fei J
    Medicine (Baltimore); 2020 Aug; 99(33):e21682. PubMed ID: 32872039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple endocrine neoplasia type 1: extensive analysis of a large database of Florentine patients.
    Marini F; Giusti F; Brandi ML
    Orphanet J Rare Dis; 2018 Nov; 13(1):205. PubMed ID: 30428914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.
    Coriat R; Walter T; Terris B; Couvelard A; Ruszniewski P
    Oncologist; 2016 Oct; 21(10):1191-1199. PubMed ID: 27401895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.